Search results
Results From The WOW.Com Content Network
For example, Purdue Pharmaceuticals entered an agreement with the United States, pleading guilty to felony misbranding of OxyContin with intent to defraud and mislead under sections 33 1(a) and 333(a)(2) of the FD&C Act and agreed to pay more than $600 million, but only $160 million was allocated to resolve civil claims under the False Claims ...
Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and Medicaid fraud, off-label promotion, and inadequate manufacturing practices. [ 3 ] [ 4 ] With respect to off-label promotion, specifically, a federal court recognized off-label promotion as a violation of the False Claims Act ...
On December 9, 2016, pharmaceutical company Bristol-Myers Squibb agreed to pay $19.5 million to settle claims with forty-three state attorneys general concerning the alleged off-label promotion of its schizophrenia drug Abilify. [50] The lawsuit alleged the company promoted the drug for use in pediatric populations and to treat dementia and ...
CVS and Walgreens. $10.7 billion. CVS and Walgreens have agreed to settle lawsuits brought against the companies by several states for their alleged role in the opioid crisis. CVS would pay nearly ...
Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.
The lawsuit is the latest to accuse employer-sponsored health plans of failing to negotiate lower prices for drugs on behalf of participants, as prescription drug costs continue to rise sharply in ...
The drugmaker has settled a series of lawsuits related to Zantac over the past 12 months, including several in California. California is generally seen as a more challenging legal environment for ...
Franklin v. Parke-Davis is a lawsuit filed in 1996 against Parke-Davis, a division of Warner-Lambert Company, and eventually against Pfizer (which bought Warner-Lambert in 2000) under the qui tam provisions of the False Claims Act. [1]